CELG News 143.83 04/21/2014 20:05:33 Celgene Corp (CELG)
Post# of 273311
Posted On: 04/21/2014 9:05:39 PM
Celgene Corp (CELG) 143.83 $CELG
What to Watch for in Biotech Earnings This Week
George Budwell, The Motley Fool - Motley Fool - 2 hrs 35 mins ago
Biotech stocks started the year off on a tear but have moved lower lately in dramatic fashion. For instance, the iShares Nasdaq Biotech Index is now down over 2% for the year, after gaining double digits at one point in early February. Pundits and...
Midday Glance: Biotechnology companies
AP - Mon Apr 21, 12:20PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Jim Cramer: We're Still in the Tech Woods
at The Street - Mon Apr 21, 10:25AM CDT
When people attach such frothy numbers to IPOs, we have problems.
Early Glance: Biotechnology companies
AP - Mon Apr 21, 9:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Jim Cramer: We're in the Grips of a Struggle
at The Street - Fri Apr 18, 12:51PM CDT
Companies that are inventing incredibly important drugs go down almost every day.
Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings
at Investor's Business Daily - Fri Apr 18, 11:12AM CDT
Can biotech stocks bounce back? As recently as last month, the Medical-Biomed/Biotech group was ranked No. 1 out of IBD's 197 industries. But it's been dead last over the last four weeks, plunging 22.1%. That partly reflects growth stocks overall...
Final Glance: Biotechnology companies
AP - Thu Apr 17, 5:01PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 1:30PM CDT
Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights ...
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Watch for Celgene to Potentially Pullback After Gaining 1.44% Yesterday
Comtex SmarTrend(R) - Wed Apr 16, 4:02PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $139.44 to a high of $143.72. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $142.70 on volume of 3.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of Celgene After 1.44% Gain
Comtex SmarTrend(R) - Wed Apr 16, 4:02PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $139.44 to a high of $143.72. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $142.70 on volume of 3.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
The S&P 500's 3 Biggest Biotech Losers of 2014
Keith Speights, The Motley Fool - Motley Fool - Wed Apr 16, 1:30PM CDT
What goes up must come down. The law of gravity applies to physics -- and the stock market. This has been readily apparent in 2014 with biotech stocks. After taking the world by storm over the previous two years, many stocks in the sector instead...
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
3 Biotech Opportunities Following This Selloff
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 8:30AM CDT
Since the end of February, the iShares NASDAQ Biotechnology Index has been hammered by about 19%. The most speculative companies have been the hardest hit, but several gems (with marketed products driving growth) have also taken a beating. ...
Anacor Pharma Remains Over-Valued on Development of Inferior Drugs
at The Street - Wed Apr 16, 7:00AM CDT
Investors have yet to fully bake in risks of Anacor's two lead drugs flopping commercially.
'Fast Money' Recap: Impressed by Yahoo!
at The Street - Wed Apr 16, 4:00AM CDT
The trading panel discussed Yahoo!'s earnings and Alibaba's IPO.
What to Watch for in Biotech Earnings This Week
George Budwell, The Motley Fool - Motley Fool - 2 hrs 35 mins ago
Biotech stocks started the year off on a tear but have moved lower lately in dramatic fashion. For instance, the iShares Nasdaq Biotech Index is now down over 2% for the year, after gaining double digits at one point in early February. Pundits and...
Midday Glance: Biotechnology companies
AP - Mon Apr 21, 12:20PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Jim Cramer: We're Still in the Tech Woods
at The Street - Mon Apr 21, 10:25AM CDT
When people attach such frothy numbers to IPOs, we have problems.
Early Glance: Biotechnology companies
AP - Mon Apr 21, 9:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Jim Cramer: We're in the Grips of a Struggle
at The Street - Fri Apr 18, 12:51PM CDT
Companies that are inventing incredibly important drugs go down almost every day.
Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings
at Investor's Business Daily - Fri Apr 18, 11:12AM CDT
Can biotech stocks bounce back? As recently as last month, the Medical-Biomed/Biotech group was ranked No. 1 out of IBD's 197 industries. But it's been dead last over the last four weeks, plunging 22.1%. That partly reflects growth stocks overall...
Final Glance: Biotechnology companies
AP - Thu Apr 17, 5:01PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 1:30PM CDT
Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights ...
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Watch for Celgene to Potentially Pullback After Gaining 1.44% Yesterday
Comtex SmarTrend(R) - Wed Apr 16, 4:02PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $139.44 to a high of $143.72. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $142.70 on volume of 3.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of Celgene After 1.44% Gain
Comtex SmarTrend(R) - Wed Apr 16, 4:02PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $139.44 to a high of $143.72. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $142.70 on volume of 3.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
The S&P 500's 3 Biggest Biotech Losers of 2014
Keith Speights, The Motley Fool - Motley Fool - Wed Apr 16, 1:30PM CDT
What goes up must come down. The law of gravity applies to physics -- and the stock market. This has been readily apparent in 2014 with biotech stocks. After taking the world by storm over the previous two years, many stocks in the sector instead...
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
3 Biotech Opportunities Following This Selloff
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 8:30AM CDT
Since the end of February, the iShares NASDAQ Biotechnology Index has been hammered by about 19%. The most speculative companies have been the hardest hit, but several gems (with marketed products driving growth) have also taken a beating. ...
Anacor Pharma Remains Over-Valued on Development of Inferior Drugs
at The Street - Wed Apr 16, 7:00AM CDT
Investors have yet to fully bake in risks of Anacor's two lead drugs flopping commercially.
'Fast Money' Recap: Impressed by Yahoo!
at The Street - Wed Apr 16, 4:00AM CDT
The trading panel discussed Yahoo!'s earnings and Alibaba's IPO.
(0)
(0)